TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01267214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate (Hyalgan)
Description: 1% Sodium Hyaluronate in prefilled syringe

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Osteotomy alone
Description: no injection
Study: NCT02633202

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
Study: NCT00534482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Office
Description: Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Office
Description: Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM-HI program with enhanced feedback
Description: Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIM-HI program and regular feedback
Description: Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
Study: NCT02640456

Intervention type: BIOLOGICAL
Intervention: Bacteriology
Description: Tonsillar surface swabs, tonsillar tissues, and pus aspirates.

Intervention type: PROCEDURE
Intervention: Type of surgery
Description: Surgical approach and complications.

Intervention type: BIOLOGICAL
Intervention: Biochemistry
Description: Amylase concentration i pus aspirates.

Intervention type: BIOLOGICAL
Intervention: Biochemistry
Description: Amylase concentration i pus aspirates.

Intervention type: BIOLOGICAL
Intervention: Serology
Description: Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
Study: NCT02453711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study: NCT02544516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tasks + PANSS+ IQ
Description: Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tasks
Description: Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
Study: NCT02731105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acnatac® Gel left face
Description: topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Gel right face
Description: topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acnatac® Gel right face
Description: topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Gel left face
Description: topical application
Study: NCT04539769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional BI
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long-limb BII
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long-limb RY group
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
Study: NCT00218842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized exercise
Description: individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
Study: NCT04350957

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose Imaging
Description: We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations.
Study: NCT00932178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calmer Life
Description: Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
Study: NCT02794532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: Oxygenation will be done via a high-flow nasal cannula
Study: NCT06418256

Intervention type: OTHER
Intervention: Spleen, blood and plasma collection
Description: Adult patients for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their care. One or more tubes of venous blood collected for the care will be recovered following the pre- or intra-operative assessment. Immediately following surgery, after careful examination by the pathologist in charge, the whole spleen or spleen fragments will be collected for further analysis. Whenever possible a catheter will be introduced in the splenic artery, the spleen will be flushed/rinsed with 0.1 - 2 L of cold perfusion medium then transferred to the laboratory for ex-vivo perfusion. Before and at the end of the ex-vivo perfusion, splenic blood and spleen fragments will be collected and processed for further analyses.
Study: NCT02652858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive blood pressure oscillometer (NIBP) implementation
Description: Implementation of two additional NIBP on humeral and femoral sites.
Study: NCT02736578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: Administered intravenously (IV) at 50 or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: Administered intravenously (IV) at 50 or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered as a 100 mg IV loading dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered as a 100 mg IV loading dose
Study: NCT03751930

Intervention type: OTHER
Intervention: Samples
Description: Urinary and faecal samples

Intervention type: OTHER
Intervention: Samples
Description: Urinary and faecal samples
Study: NCT00126724

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^11 DRP/mL

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: tgAAC94 placebo
Description: placebo

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^12 DRP/mL tgAAC94

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^13 DRP/mL tgAAC94

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
Study: NCT05429385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion
Study: NCT02616796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social gaze training
Description: Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
Study: NCT01906606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
Study: NCT01253577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Stent with drug coating
Description: Sinus stent coated with 370 ug of the corticosteroid mometasone furoate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non Coated Sinus Stent
Description: Sinus stent (visually identical) without drug coating
Study: NCT04656327

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
Study: NCT01311141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doripenem
Description: doripenem once i.v.500mg
Study: NCT03182569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXIBLE CATHETER

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hourly rigid needle puncture
Study: NCT00851227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous
Study: NCT04485351

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02379637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03959397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel monotherapy or combination therapeutic regimen
Study: NCT03064061

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality
Description: a device with virtual reality is given to the patients with a film of 18 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: a device with virtual reality is given to the patients with a film of 18 minutes
Study: NCT01091220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
Study: NCT02612519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implantation of Alfapump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implantation of Alfapump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS
Description: Implantation of TIPS
Study: NCT04251026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose
Study: NCT04610593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
Study: NCT02722018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase II Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase II Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase II Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase III Prototype Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase III Prototype Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase III Prototype Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
Study: NCT01808105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Formula
Description: Feeding ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula 1
Description: Feeding ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula 2
Description: Feeding ad libitum

Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk
Description: Feeding ad libitum
Study: NCT02510560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRA-2112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRA-2112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00614068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
Study: NCT04515238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o.
Study: NCT02254954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan in combination with RT and TMZ
Description: Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
Study: NCT02001636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resource Instant Protein 88
Description: Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resource Maltodextrin
Description: Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
Study: NCT00495248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention inspired by Lifestyle Redesign
Description: Group intervention inspired by Lifestyle Redesign
Study: NCT04071600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuropeptide Y
Description: Intranasal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal
Study: NCT02791100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of chicken eggs
Description: Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
Study: NCT04639596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity, bowling, (SRT).
Description: This study will be a prospective randomized controlled trial (RCT) of Mindfulness-based Therapeutic Sailing (MBTS) versus a standard recreation therapy activity (bowling) among Veterans with psychiatric and/or substance use disorders.